Legion Therapeutics
Legion Therapeutics is a dual-use drug development company focused on increasing U.S. military readiness by creating therapeutics for warfighters and civilians. Its pipeline includes Ln-101, a circular RNA therapy that promotes muscle growth without systemic hormonal effects, and Ln-102, a bioscavenger designed to protect against fentanyl exposure. The company leverages modular AI and robotics capabilities to advance candidates from target identification through the preclinical stage.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
- Defense Tech
- Artificial Intelligence
- Robotics
- Hardware
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
U.S. military readiness is constrained by lengthy training timelines and vulnerability to chemical threats such as synthetic opioids, which also drive a civilian overdose crisis. Conventional therapeutics development is slow and often lacks the dual-use focus needed to serve both warfighter and public health needs.
Solution
Legion Therapeutics provides a dual-use drug development infrastructure that scales non-dilutive defense capital to de-risk therapeutics relevant for warfighters and global markets. The company leverages modular AI and robotics capabilities to move candidates from target identification through preclinical stages, enabling faster, more efficient development. Its pipeline includes Ln-101, a circular RNA therapy that selectively delivers Ln-1 to skeletal muscle to promote hypertrophy and repair without systemic hormonal effects. Ln-102 is a bioscavenger designed to protect against fentanyl and related synthetic opioid exposure. A third candidate, Ln-201, is a buccal appetite regulator targeting visceral fat reduction and appetite control to optimize health and lifespan.
Target Audience
Primary customers are U.S. Department of Defense entities and military research organizations, with secondary applications for civilian medical markets seeking treatments for muscle loss, opioid exposure, and metabolic health.
Features
- Ln-101: circRNA-based therapy delivering Ln-1 selectively to skeletal muscle via systemic administration for hypertrophy, repair, and vascularization without elevating systemic hormone levels
- Ln-102: bioscavenger for prophylaxis against fentanyl and its analogs, addressing the leading cause of death for Americans aged 18-45 at 195 U.S. citizens per day
- Ln-201: buccal appetite regulator for reducing visceral fat and controlling excessive hunger
- Modular AI-driven pipeline from target discovery to pre-IND stage with integrated high-throughput robotics capabilities
- Dual-use positioning covering military casualty reduction and civilian medical spin-outs